Inside Rx has provided patients with $160 million in savings on brand and generic medications since its inception in May 2017
- Newly added therapies may now offer more affordable access to drugs for the treatment of cancer and nasal polyps
- New products expand access for anti-fungal, acne, asthma, COPD and topical steroids treatment as well as prescribed medications for the management of heart health and infections
- Inside Rx adds two new manufacturers to the list of 19 pharmaceutical companies working with the program to offer deep discounts to uninsured and underinsured patients
PR Newswire
FRANKLIN LAKES, N.J., Sept. 5, 2018